Skip to Content

Acalabrutinib Shows Promise for Elderly CLL Patients

At ASH 2024, Dr. Florian Simon shared findings from a trial evaluating acalabrutinib for treating CLL in patients aged 80 and older. The results showed a 93% response rate and significant frailty improvements after six months of treatment, highlighting the drug’s efficacy and safety for older, frail populations while emphasizing tailored approaches for those with cardiac comorbidities.

Florian Simon

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top